Genky DrugStores (9267) Fundamentals 2026 — P/E 14.4x, Revenue Analysis | SniperIQ
Genky DrugStores (9267) is a JP-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥112.6B, trading at ¥3695.00 on the JPX. This SniperIQ fundamentals page covers Genky DrugStores's valuation (P/E 14.4x, P/B 1.9x), profitability (net margin 3.6%), revenue (¥200.8B in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Genky DrugStores's market cap?
Genky DrugStores (9267) has a market capitalization of approximately ¥112.6B, trading at ¥3695.00 on the JPX. Market cap moves with the live share price.
What is Genky DrugStores's P/E ratio?
Genky DrugStores's trailing twelve-month P/E ratio is 14.4x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Genky DrugStores?
Genky DrugStores runs a net profit margin of 3.6%, a gross margin of 20.4%, and an operating margin of 5.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Genky DrugStores generate?
Genky DrugStores reported revenue of ¥200.8B for fiscal year 2024, with net income of ¥7.1B and earnings per share (EPS) of 232.49. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Genky DrugStores pay a dividend?
Genky DrugStores offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Genky DrugStores financially healthy?
Genky DrugStores carries a debt-to-equity ratio of 0.65x and a current ratio of 0.94x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Genky DrugStores a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genky DrugStores (9267) the key facts are: market cap ¥112.6B, P/E 14.4x, revenue ¥200.8B, 52-week range 3175-5460. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Genky DrugStores's full fundamentals live
Get Genky DrugStores's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.